RESEARCH ARTICLE

The risks and benefits of providing HIV services during the COVID-19 pandemic

John Stover, Sherrie L. Kelly, Edinah Mudimu, Dylan Green, Tyler Smith, Isaac Taramusi, Loveleen Bansi-Matharu, Rowan Martin-Hughes, Andrew N. Phillips, Anna Bershteyn

1 Avenir Health, Glastonbury, CT, United States of America, 2 Burnet Institute, Melbourne, VIC, Australia, 3 Department of Decision Sciences, University of South Africa, Pretoria, South Africa, 4 Cooper/Smith, Washington, DC, United States of America, 5 National AIDS Council of Zimbabwe, Harare, Zimbabwe, 6 Institute for Global Health, University College London, London, United Kingdom, 7 New York University School of Medicine, New York, NY, United States of America

* Jstover@AvenirHealth.org

Abstract

Introduction

The COVID-19 pandemic has caused widespread disruptions including to health services. In the early response to the pandemic many countries restricted population movements and some health services were suspended or limited. In late 2020 and early 2021 some countries re-imposed restrictions. Health authorities need to balance the potential harms of additional SARS-CoV-2 transmission due to contacts associated with health services against the benefits of those services, including fewer new HIV infections and deaths. This paper examines these trade-offs for select HIV services.

Methods

We used four HIV simulation models (Goals, HIV Synthesis, Optima HIV and EMOD) to estimate the benefits of continuing HIV services in terms of fewer new HIV infections and deaths. We used three COVID-19 transmission models (Covasim, Cooper/Smith and a simple contact model) to estimate the additional deaths due to SARS-CoV-2 transmission among health workers and clients. We examined four HIV services: voluntary medical male circumcision, HIV diagnostic testing, viral load testing and programs to prevent mother-to-child transmission. We compared COVID-19 deaths in 2020 and 2021 with HIV deaths occurring now and over the next 50 years discounted to present value. The models were applied to countries with a range of HIV and COVID-19 epidemics.

Results

Maintaining these HIV services could lead to additional COVID-19 deaths of 0.002 to 0.15 per 10,000 clients. HIV-related deaths averted are estimated to be much larger, 19–146 discounted deaths per 10,000 clients.
Discussion

While there is some additional short-term risk of SARS-CoV-2 transmission associated with providing HIV services, the risk of additional COVID-19 deaths is at least 100 times less than the HIV deaths averted by those services. Ministries of Health need to take into account many factors in deciding when and how to offer essential health services during the COVID-19 pandemic. This work shows that the benefits of continuing key HIV services are far larger than the risks of additional SARS-CoV-2 transmission.

Introduction

Many health services, including those providing HIV prevention, testing and care, have been restricted during the COVID-19 pandemic because services have been closed for some periods of time, capacity has been limited, or people were reluctant to access health services because of the risk of becoming infected. WHO released guidelines for essential health services that prioritized maintaining services for antiretroviral therapy (ART) [1]. Data reported to UNAIDS by 22 countries from all regions of the world on monthly HIV service provision illustrates the extent of the problem [2]. These data show severe reductions in diagnostic testing, numbers of people newly initiating ART, viral load testing, programs to prevent mother-to-child transmission of HIV (PMTCT), services for key populations, voluntary medical male circumcision (VMMC), public sector condom distribution, and pre-exposure prophylaxis (PrEP). The severity of disruption varies by country and time but was as high as 75% in some cases. Service levels rebounded quickly to pre-COVID-19 levels for some services (PMTCT, key population services, VMMC, PrEP) in some countries but remained low through September 2020 for others. In early 2021 increases in COVID-19 cases led some countries to re-impose lockdown measures.

For example, consider the situation in Zimbabwe. At the end of March 2020, Zimbabwe released guidance for several HIV services [3]. For VMMC, all road shows, sports galas and other events were suspended, traditional/religious circumcision camps were shuttered and VMMC services limited to walk-ins only. Guidance for HIV testing prioritized self-testing and limited facility-based testing to priority populations. For PrEP and ART multi-month dispensing was encouraged as well as efforts to limit crowding by revising visit schedules. Level 5 lockdown measures were re-imposed for 30 days in January 2021. These restrictions include restricted opening hours for essential services, closure for non-essential services, restrictions on attendance at funerals and weddings, limited public transportation services and staying at home except for buying food and medicines or transporting sick relatives. Similar restrictions were imposed in Malawi leading to only 33% of the expected VMMCs and large reductions in PrEP initiation and use.

Restricting some services makes sense if the benefits of those services are small compared to the potential harm of additional COVID-19 transmission. If the benefits are large, then there will be advantages to continuing those services even if it means some additional COVID-19 transmission and deaths. The purpose of this paper is to examine the benefits and disadvantages of providing HIV services during the COVID-19 pandemic.

Methods

We used four existing HIV simulation models to estimate the HIV-related deaths that would be averted through delivery of HIV services had they been available and three existing...
COVID-19 simulation models to estimate the additional COVID-related deaths that could happen as a result of keeping the HIV services open. The use of existing models, rather than constructing a new model with both HIV and COVID-19 allowed us to involve several modeling groups and use models that had already been calibrated to several different settings.

We used multiple models for both COVID-19 and HIV to remove some of the uncertainty about model assumptions and fits to country data. The results from different models will vary because of differences in model structure and assumptions as well as different modeling teams. If there is consensus on the main results in spite of these differences, it indicates that the conclusions are robust and relieves the reader of the need to understand the details of each individual model.

The COVID models looked at the possibilities of additional transmission from infected patients to health care workers and vice versa as well as potential transmission during patient travel to and from health clinics and thereafter within the household and beyond to the general population. COVID-19 and HIV were compared on the basis of additional COVID-19 deaths caused by continuing HIV services and HIV-related deaths averted. Since COVID-19 deaths would occur immediately and HIV-related deaths would occur later, possibly 30 years or more later if patients with new infections receive antiretroviral therapy (ART), we discounted all HIV-related deaths to the present year using a 3% annual discount rate as recommended for comparisons of this type [4]. Different models were applied to different countries with different levels of HIV and COVID-19 epidemics as described below. To ease comparisons across countries, all results are reported per 10,000 people receiving each HIV service.

The HIV services we examined included: the provision of voluntary medical male circumcision (VMMC) which reduces susceptibility to HIV transmission, HIV diagnostic testing which provides an entryway into treatment, viral load testing which determines whether ART is successfully controlling HIV, and programs to prevent mother-to-child transmission (PMTCT) which provides HIV testing and antiretroviral therapy to prevent transmission of HIV from mother to newborn. We did not include antiretroviral treatment in this analysis since previous work [5] has already shown the enormous benefits to continuing treatment services and most programs have followed guidelines and prioritized continuing these services. PrEP was not included because of the slow rollout of PrEP programs to date.

We use modeling results from different countries to take advantage of country calibrations that have been done previously. Direct comparisons between COVID-19 deaths and HIV deaths averted in the same country are only possible for Malawi and South Africa, but we also compare the range of results across many countries to understand the variations in results.

HIV models

The four HIV simulation models are described below. In each case, the team responsible for developing the model applied it to one or more countries using the best available data on HIV prevalence, behaviors and treatment over time. Table 1 compares key model characteristics. A more complete comparison can be found elsewhere [5].

Goals model. Goals is a compartmental HIV simulation model developed by Avenir Health [6]. It divides the adult population by sex and risk behaviors (not sexually active, one sexual partner in the last year, more than one sexual partner in the last year, female sex workers, male clients of sex workers, men who have sex with men and injecting drug users). HIV transmission occurs due to contact between an HIV-infected and HIV-uninfected individual. The probability of transmission is determined by the basic transmissibility of the virus and the characteristics of the contact, including the direction of transmission (male-to-female or female-to-male), the type of contact (heterosexual sex, male-male sex, needle sharing), stage of
infection, presence of another sexually transmitted infection in either partner, condom use, male circumcision, viral suppression through ART, and use of pre-exposure prophylaxis (PrEP), the number of contacts per partner and the number of partners per year. Behavior change interventions affect transmission by changing risk behaviors, such as condom use, number of partners or age at first sex. People living with HIV are tracked over time by age, CD4 category and ART status. Mortality depends on age, CD4 count, and ART status. The model was applied to countries with different levels of HIV prevalence (India 0.22%, Kenya 4.5%, Malawi 8.9%, Nigeria 1.3%, South Africa 19% and Zimbabwe 12.8% in 2019) and COVID-19 cumulative cases reported per 10,000 population (India 75, Kenya 20, Malawi 4, Nigeria 4, South Africa 183 and Zimbabwe 10, as of December 2020). The model was used to estimate the impact of services for VMMC, condom distribution, HIV testing and PMTCT services.

**HIV synthesis.** The HIV Synthesis model is an individual-based model of sexual behaviour, transmission and progression of HIV and the effect of ART in an adult population updating in 3 month time steps. For each model run we sample from distributions of parameters and generate a range of “setting scenarios” which we consider reflect the diversity of epidemic and programmatic situations in sub-settings within countries sub-Saharan Africa, as well as reflecting uncertainty over some parameter values. The effect of opening three services is modelled: HIV testing, viral load monitoring and ART switching, and VMMC. We assume that each of these stopped on 1st April 2020. We then consider 5 service resumption policies: (i) all three services remain unavailable until 1 July 2021; (ii) viral load monitoring and ART switching are resumed on 1 July 2020, HIV testing and VMMC remain unavailable until 1 July 2021; (iii) HIV testing is resumed on 1 July 2020; Viral load monitoring and ART switching and

### Table 1. Key characteristics of the HIV models.

| Goals | Optima HIV | HIV Synthesis | EMOD |
|-------|------------|---------------|------|
| Structure | Compartment model for population 15–49 with 11 risk groups | Compartment model with age, sex and risk group disaggregation | Individual-based stochastic model | Individual-based stochastic model |
| Calibration | Epidemic parameters adjusted to fit surveillance and survey data | Epidemic parameters adjusted to fit surveillance and survey data | Epidemic parameters varied to generate a large number of scenarios from which those matching specified characteristics can be selected | Epidemic and behavioral parameters varied to create simulations which are matched to surveillance and survey data. 250 parameter sets are selected to represent plausible fits. |
| Sexual and injecting behavior | Regular, casual and commercial sex; men having sex with men; people who inject drugs | Regular, casual and commercial sex; men having sex with men; people who inject drugs | Short- and long-term condomless sexual partners | Marital, informal, transitory and commercial partnerships |
| HIV acquisition determinants | Number and types of partners, acts per partner, condom use, male circumcision status, PrEP use, STI prevalence, viral suppression through ART, stage of infection | Number of partners, acts per partner, condom use, male circumcision status, PrEP use, viral suppression through ART, stage of infection, type of sex | Type of condomless sex partnership, PrEP use, circumcision and (sexually active) community viral load | Number and types of partners, acts per partner, condom use, male circumcision status, PrEP use, STI prevalence, viral suppression through ART, stage of infection |
| MTCT | CD4 count of mother or type of prophylaxis, retention, duration of breastfeeding | CD4 count of mother or type of prophylaxis, duration of breastfeeding | Viral load of mother at birth | CD4 count of mother or type of prophylaxis, retention on prophylaxis |
| Settings | India, Kenya, Malawi, Nigeria, South Africa, Zimbabwe | 38 countries* | Applied to a range of settings that encompass most epidemics in sub-Saharan Africa | South Africa |

* Argentina, Armenia, Belarus, Brazil, Bulgaria, Cambodia, Colombia, Democratic Republic of the Congo, Eswatini, Ethiopia, Haiti, India, Iran, Kazakhstan, Kenya, Kyrgyzstan, Macedonia (Former Yugoslav Republic), Malawi, Mexico, Moldova, Mozambique, Nepal, Nigeria, Papua New Guinea, Peru, Russian Federation, Senegal, South Africa, Sudan, Tajikistan, Tanzania, Thailand, Togo, Uganda, Ukraine, Uzbekistan, Vietnam, and Zimbabwe.

https://doi.org/10.1371/journal.pone.0260820.t001
VMMC remain unavailable until 1 July 2021; (iv) HIV testing and Viral load monitoring and ART switching are resumed on 1 July 2020, VMMC remain unavailable until 1 July 2021; (v) all three services are resumed on 1 July 2020. We assume that people on ART are able to continue taking ART throughout this period (i.e., that this service is not disrupted), but the suspension of HIV testing impacts on ART initiations. The effect of resuming HIV testing on numbers of deaths per 10,000 people receiving the service is derived from the difference between policies (i) and (iii), the effect of resuming viral load monitoring from the difference between policies (i) and (ii), and the effect of resuming VMMC services from the difference between policies (iv) and (v).

**Optima HIV.** The Optima HIV model is a compartmental model with populations disaggregated by sex, age, and risk. Models for 38 countries (Argentina, Armenia, Belarus, Brazil, Bulgaria, Cambodia, Colombia, Democratic Republic of the Congo, Eswatini, Ethiopia, Haiti, India, Iran, Kazakhstan, Kenya, Kyrgyzstan, Macedonia (Former Yugoslav Republic), Malawi, Mexico, Moldova, Mozambique, Nepal, Nigeria, Papua New Guinea, Peru, Russian Federation, Senegal, South Africa, Sudan, Tajikistan, Tanzania, Thailand, Togo, Uganda, Ukraine, Uzbekistan, Vietnam, and Zimbabwe) were used in this analysis. The effect of opening each HIV service was modelled in countries based on where HIV services were implemented in a comparable format. This included nine countries in sub-Saharan Africa with coverage disaggregated by VMMC and traditional circumcision, 19 countries with viral load monitoring coverage disaggregated from ART, and all 38 countries for HIV testing. ART and PMTCT coverage were held constant over the study period to reflect 2020 values for the proportion of people diagnosed with HIV, while coverage of other programs was held constant based on the latest reported spending. Where extended disruptions occurred to VMMC, it was assumed that VMMCs would be deferred to the 12-months following the resumption of service coverage rather than not occurring.

The same analysis approach described above for the HIV Synthesis model was used. The number of client visits averted by not re-opening services was based on the assumption that each HIV test, each viral load test, and each voluntary medical male circumcision consisted of one client visit, giving the deaths averted per 10,000 clients as 
\[
\frac{\text{discounted number of client visits avoided in 2020 and 2021}}{10,000} \times \text{discounted additional HIV-related deaths from 2020 to 2050}
\]
Models were run independently over 50 years with reopening of each service on 1 July 2020 compared with 1 July 2021. A 2.4-month time step was applied, with a resulting 5-timesteps per year. Mean estimates are reported (weighted by the number covered by each service for each country) with uncertainty given as the 25th and 75th percentile for individual countries to capture the variation across countries representing local conditions.

**EMOD.** EMOD-HIV is a network transmission model of HIV [7] built into the open-source individual-based modeling framework EMOD [8]. HIV transmission is simulated at the level of each coital act between sexual partners, who form an age/sex-structured network of relationships of variable duration [9]. The model was fit to epidemic patterns in South Africa including programmatic data on HIV treatment and survey estimates of age/sex-specific HIV incidence and prevalence by adjusting parameters related to sexual risk behavior and engagement in care, as described elsewhere [10–12]. Age/sex-specific risk of non-HIV deaths were applied to the population based on demographic projections from the United Nations Population Division, and a competing risk of HIV-associated death was applied to PLHIV on ART and not on ART. For PLHIV not on ART, risk of HIV-associated death depends on age at time of infection, with older adults progressing more rapidly toward AIDS and death. For PLHIV on ART, risk of HIV-associated death depends on age, sex, and CD4 count at time of ART initiation and level of ART adherence, with declining risk of death on ART for adherent patients who remain stable on ART [13]. For individuals who interrupt and resume ART, risk
of death calculated based on CD4 count at time of interruption and re-engagement in ART [14]. We compared the number of HIV-associated deaths in model projections with different durations of service disruption, as described above for the HIV Synthesis model, applied to the services of HIV testing, VMMC, and PMTCT. The number of interventions delivered was calculated in order to obtain the ratio of the difference in the number of deaths to the difference in the number of clients served, and the ratio was multiplied by 10,000 in order to obtain the reported results. Because EMOD-HIV is a stochastic model, simulations were run 250 times and 95% uncertainty intervals were reported, with the constraint that delivery of the services could not increase the number of HIV-associated deaths due to stochastic effects.

**COVID-19 models**

Three COVID-19 simulation models were applied to estimate the potential COVID-related deaths that could occur due to transmission related to HIV services. Table 2 summarizes the key characteristics of the COVID-19 models.

**Contact model.** We developed a simple contact model of COVID-19 transmission based on an approach developed by Abbas et al. to examine the risks related to childhood immunization [15]. We estimate potential new infections among health care workers, clients and the general public. New infections among health care workers \( I_{HW} \) are estimated as:

\[
I_{HW} = (1 - (1 - p \times (1 - e))^w) \times R_0
\]

Where \( p \) is the prevalence of infectious SARS-CoV-2 in the population, \( e \) is the effectiveness of personal protective equipment used by health care workers (set at 90%), \( w \) is the number of health care workers that have contact with each client and \( R_0 \) is the average number of people who will contract an infection from one infected person (which accounts for onwards transmission from the health care worker).

Client infections at health care settings are estimated as:

\[
I_c = (1 - (1 - p \times (1 - e))^w) \times R_0
\]

where \( p' \) is the prevalence of infections SARS-CoV-2 in health care workers. This is assumed to be lower than the general population due to the use of personal protective equipment.

For client contact with the general public during travel to and from, and while awaiting, services the probability of infections is estimated as:

\[
I_t = (1 - (1 - p \times r)^n) \times R_0
\]

where \( r \) is the probability of infection given contact with an infectious person during travel or in the waiting area and \( n \) is the number of contacts during travel to and from the clinic or in the clinic waiting area.

| Table 2. Key characteristics of the COVID-19 models. |
|--------------------------------------|-----------------|-----------------|
| **Contact Model**                      | Cooper/Smith               | COVASIM         |
| Structure                             | Single age compartment model | Compartamental age-structured model implemented at sub-distric level. | Agent-based age and sex structured model. |
| Type of contacts                      | Patient contact with health care workers, general public during transportation to clinic, and with the family | Age contact matrix | Contact network matrices for home, school, workplace and community |
| Calibration                           | Reported new daily cases and reported COVID-19 deaths | Adjusted estimates of new cases, prevalent cases and COVID-19 deaths | Daily COVID-19 cases, deaths and tests |
| Setting                               | Kenya, Malawi, Nigeria, South Africa, Zimbabwe, India | Malawi | Kwa-Zulu Natal, South Africa |

[https://doi.org/10.1371/journal.pone.0260820.t002](https://doi.org/10.1371/journal.pone.0260820.t002)
The population prevalence of infectious SARS-CoV-2 is estimated as the average reported number of daily new cases of COVID-19 multiplied by the average duration of the infectious period (5–11 days [16]) divided by the adult population size. While new daily cases are likely to be under-reported [17] leading to an under-estimate of new COVID-19 cases, we also calculate the COVID-19 mortality rate from the reported COVID-19 cases and deaths so that the two measures will be consistent.

The number of deaths due to COVID-19 is estimated as the number of new infections multiplied by the mortality rate and adjusted for the age. The majority of COVID-19 deaths occur to people over the age of 65. Health care workers and clients are likely to be much younger. We adjust the population mortality rate downward to account for these age effects. In the United States the age group 35–44 accounts for 1.8% of all COVID-19 [18] deaths and 16.4% of COVID-19 cases [19], so the population mortality is multiplied by 0.11 to account for the age effects.

Cooper/Smith COVID model. We developed a deterministic, compartmental, age-structured transmission model for COVID-19 down to the sub-district level in Malawi beginning on April 1st for one year. The model has a SEIR structure and estimates infections, hospitalization need, intensive care need, and deaths and includes daily estimates of cloth mask utilization and physical distancing. We adjust the risk of severe disease resulting in hospitalization, intensive care, and death according to age using age-specific rates from the literature. Finally, community spread of COVID-19 did not begin on the same date in each sub-district. In lieu of sufficiently granular testing data, we estimate each sub-district’s epidemic start date by leveraging estimates of connectedness between sub-districts from mobile phone data. These daily estimates of connectedness act as a likelihood of transmission based on the pool of susceptibles and infectious individuals in source and sink sub-districts, respectively.

Surveillance of infections, hospitalizations, and deaths are highly limited in Malawi, with one of the lowest testing rates in the world and very limited death registration. We triangulate limited seroprevalence estimates in Malawi, with seroprevalence estimates from other settings including South Africa in combination with their respective test rates. We estimate that actual infections of COVID-19 in Malawi may be undercounted by 500-times, while COVID deaths are undercounted by approximately 12-times. We adjusted model parameters (within sensible range of literature review estimates) including R0, generation time, and hospitalization risk to align the projection with the calibrated trajectory of infections and deaths.

Over one year, we estimate approximately 3,500,000 COVID-19 infections and 6,600 deaths among adults. We then estimate what proportion of infections and deaths are attributable to HIV service delivery as those services are a proportion of total close contacts with similar transmission probability. We estimate under a range of HIV service delivery scenarios that those services contribute approximately 1.2%-2.5% of total contacts–and therefore that same proportion of infections and deaths. We express these COVID-19 infections and deaths as a rate per 10,000 HIV clients, and break results down by service type.

Covasim. Covasim is an agent-based, age-and sex-structured SEIR model for COVID-19 transmission. A model for KwaZulu-Natal, South Africa was informed using estimates for household size distribution and contact network matrices (for home, school, workplace, and the community by 5-year age bands) and was calibrated to daily numbers of COVID-19 cases, deaths and tests using changes in viral transmission to reflect implementation of different COVID-19 policies over time. The model was also informed by global COVID-19 disease parameter estimates as described by Kerr et [20]. To simulate conditions used in the Contact model described above, contact with two (HIV, viral load testing) or three (VMMC, PMTCT) healthcare workers were specified and the probability of transmission per contact with an infectious member in the community was set to 6% [15]. Transmission was simulated for
1-year from 1 March 2020. SARS-CoV-2 infections and COVID-19 deaths as a result of VMMC, HIV testing, viral load testing, or PMTCT service-related exposure were estimated and expressed per 10,000 HIV clients. A ratio of COVID-19 mortality for those aged 35–44 years to the total population of 0.11 was assumed following the Contact model approach.

### Results

Our simulations estimate that the additional COVID-19 deaths per 10,000 in-person HIV service clients ranges from 0.002 to 0.155 across all countries and models while the additional HIV-related deaths averted by keeping those services open range from 19 to 146. The average ratio of discounted HIV-related deaths to COVID-19 deaths ranges from 140 for HIV testing to 740 for VMMC services. Table 3 shows the detailed results by model and service. Table 4 compares results just for Malawi and South Africa and shows a similarly large benefit in averting HIV deaths.

### Discussion

Our results clearly show that the potential increase in HIV transmission and subsequent death that would be associated with curtailing HIV services during the COVID-19 pandemic are

---

**Table 3. COVID-19 deaths among health care workers, clients and family members due to transmission during access to HIV services and HIV-related deaths that could be averted by these services per 10,000 clients.**

| HIV Service  | Additional COVID-19 Deaths | HIV-Related Deaths Averted |
|--------------|-----------------------------|----------------------------|
|              | Contact Model | Cooper-Smith | Covasim | Goals | HIV Synthesis | Optima HIV | EMOD |
| VMMC         | 0.01–0.24      | 0.004        | 0.098   | 19 (10–30) | 115 (4–235) | 103 (4–223) | 92 (0–323) |
| HIV testing  | 0.00–0.17      | 0.152        | 0.004   | 22 (20–35) | 22 (17–26)  | 22 (12–42)  | 14 (6–22)  |
| Viral load testing | 0.00–0.17 | 0.152    | 0.004   | 44 (27–61) | 49 (39–275) |                 |         |
| PMTCT        | 0.01–0.24      | 0.002        | 0.098   | 33 (0–100) | 44 (0–358)  |                 |         |

Note: Figures in parentheses represent 95% confidence bounds (95% confidence interval for mean across setting scenarios for HIV Synthesis). Ranges for the Contact Model are across 6 countries. Different models were applied to different countries as specified in methods section. The rate of mortality is the unweighted averaged across the countries for which the analysis was conducted.

---

**Table 4. Results for Malawi and South Africa per 10,000 clients.**

|         | Additional COVID-19 Deaths | HIV-Related Deaths Averted |
|---------|-----------------------------|----------------------------|
|         | Contact Model | Cooper-Smith | Covasim | Goals | HIV Synthesis | Optima HIV | EMOD |
| Malawi  |              |              |         |       |               |           |     |
| VMMC    | 0.03          | 0.004        | 0.098   | 83    | 413           | 1          |     |
| HIV testing | 0.02   | 0.152        |         | 35    | 12            | 8          |     |
| Viral load testing | 0.02 | 0.152 |         | 35    | 66            | 33         |     |
| PMTCT   | 0.03          | 0.002        | 0.098   | 33    |               |            |     |

|         | Additional COVID-19 Deaths | HIV-Related Deaths Averted |
|---------|-----------------------------|----------------------------|
|         | Contact Model | Cooper-Smith | Covasim | Goals | HIV Synthesis | Optima HIV | EMOD |
| South Africa |                |               |         |       |               |           |     |
| VMMC    | 0.24          | 0.098        | 77      | 175   | 4             | 92         |     |
| HIV testing | 0.17   | 0.004        | 22      | 36    | 45            | 14         |     |
| Viral load testing | 0.17 | 0.004 | 22      | 48    | 42            |            |     |
| PMTCT   | 0.24          | 0.098        | 100     |       |               |            | 44 |

- Restricted to setting scenarios with HIV prevalence in the range [12.1–24.7] in 2020 for South Africa (n = 263) and 7.0–9.0 for Malawi (n = 123).
many times larger than the expected COVID-19 deaths due to transmission during visits to access HIV services. COVID-19 deaths would have to be at least 1000 times higher than we estimated to result in an equivalent number of deaths.

As indicated by the ranges for the HIV outcomes in Table 1 these results are robust to uncertainties in model estimates. However, the results are sensitive to assumptions regarding the annual discount rate and the time from HIV-infection until HIV-related death. Without ART the median survival with HIV is about 11 years. With a 3% discounting rate, an additional death that occurs in 2031 (consistent with the 11-year median HIV survival time in the absence of treatment) would be discounted by a factor of 1.4 while an additional death that is postponed to 2050 due to treatment would be discounted by a factor of 2.5. A somewhat higher discount rate may be appropriate for many developing countries [21]. However, the discount rate would need to be as high as 18% to bring the discounted HIV down to the level of the COVID-19 deaths.

This result derives mostly from the differential mortality rates of the two diseases. Untreated HIV generally leads to death although a person with drug sensitive virus who takes their regimen every day is unlikely to die from HIV, even after 30 or 40 years [22]. If HIV is controlled long enough, a person living with HIV may die from some other cause before dying of HIV. In comparison, COVID-19 is rarely fatal. By the end of 2020 85 million cases and 1.8 million deaths had been reported globally, implying a mortality rate of about 2%. Although deaths are certainly under reported, the number of cases have an even larger under count. Most COVID-19 deaths are in older populations and in those with comorbidities. The mortality of people in their 30s and 40s may be about 0.2%. Of course, both COVID-19 and HIV also produce disabilities, besides. Only HIV-associated disabilities were considered in this study. Long-term disabilities among survivors of COVID-19 are not yet well-characterized due to the novelty of the virus [23].

The results presented here come from seven different models applied to different sets of countries and settings. The variation in the results largely reflect those differences. There are also differences in model structure relating to how age and risk behaviors are handled that affect the results. The modeling teams often made different assumptions about how to interpret available data and which dynamics were important to model explicitly. The models agree surprisingly well on some results and vary by an order of magnitude on others, which we hope to explore further in future collaborations. However, in all cases the variation in estimates across models is quite small compared to the differences in estimated COVID-19-related and HIV-related mortality. In all cases the lowest estimate of HIV-related deaths averted by re-opening HIV services was at least two orders of magnitude higher than the highest estimate of additional COVID-19 related deaths as a result of re-opening HIV services. Although the models were applied to different countries, we also present results for two countries (Malawi and South Africa) with both COVID-19 and HIV models. Those results reinforce the conclusion that HIV services will prevent many more HIV deaths than COVID-19 deaths that might result from increased COVID-19 transmission.

The contact model does not account for potential immunity to SARS-CoV-2 that may have accrued among health care workers and patients prior to potential exposures related to HIV service delivery. Thus, this model is expected to produce much higher COVID-19 risk than one that accounts for accrual of immunity, and therefore should be interpreted as an upper bound to COVID-19 risk. However, this upper bound is worth considering given uncertainties about the cumulative number of SARS-CoV-2 infections in these settings, the duration and effectiveness of SARS-CoV-2 immunity in these settings, and the potential for new variants of SARS-CoV-2 to evade immune responses.
There are limitations to this analysis. COVID-19 is a new disease, so models are also new and relatively untested in projecting into the future. We have modelled HIV services in isolation but they are imbedded within a larger health system and effects of shortages of health personnel to deal with COVID-19 hospitalizations, testing and vaccination campaigns may also affect HIV services. Decision to continue a specific HIV service, such as testing, may be determined more by decisions about how to provide all types of health services rather than just those related to HIV. Disruptions to supply chains may also affect the delivery of health services. In most cases we modeled each HIV service as a single visit. Some may require two or three visits which would increase the risk of COVID-19 transmission. However, doubling or tripling the potential COVID-19 deaths still leaves them well below potential HIV-related deaths of not using the services.

Most programs have taken steps to ensure that essential HIV services such as ART re-supply can continue. Often this involves multi-month scripting to reduce the number of visits required for patients doing well on ART. Countries have learned from past epidemics, such as Ebola, how to maintain essential services under extraordinary circumstances \[24\].

Our analysis only examines the relative mortality risks and benefits of providing HIV services during the COVID-19 pandemic. Some services might still be restricted because of a lack of adequate health care workers, lack of supplies or fears of patients. These are all important factors. Our analysis is intended to show that fear of causing greater harm through additional COVID-19 deaths should not be a concern since the HIV services will avert many more HIV deaths.

Many health systems are under great strain trying to cope with the surge of hospitalizations due to COVID-19 and meanwhile maintain other essential health services, but many are finding ways to continue these important services in spite of the obstacles. These efforts are important not only for averting new HIV infections but also for averting other infectious diseases through continued childhood immunization, avoiding unintended pregnancies by continuing family planning services, avoiding increased TB transmission by continuing diagnoses and treatment programs, and for many other health challenges as well. Our efforts should focus on how to maintain these services so that we do not lose the benefits of the progress in HIV that has been made in recent years.

**Author Contributions**

**Conceptualization:** John Stover, Andrew N. Phillips.

**Formal analysis:** John Stover, Sherrie L. Kelly, Edinah Mudimu, Dylan Green, Tyler Smith, Isaac Taramusi, Loveleen Bansi-Matharu, Rowan Martin-Hughes, Andrew N. Phillips, Anna Bershteyn.

**Methodology:** John Stover, Sherrie L. Kelly.

**Writing – original draft:** John Stover, Sherrie L. Kelly, Edinah Mudimu, Isaac Taramusi, Loveleen Bansi-Matharu, Andrew N. Phillips, Anna Bershteyn.

**Writing – review & editing:** John Stover, Sherrie L. Kelly, Edinah Mudimu, Dylan Green, Tyler Smith, Isaac Taramusi, Loveleen Bansi-Matharu, Rowan Martin-Hughes, Andrew N. Phillips, Anna Bershteyn.

**References**

1. WHO. Maintaining essential health services: operational guidance for the COVID-19 context interim guidance. June 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-essential-health-services-2020.1
2. UNAIDS. HIV Service Disruptions in 2020. November 2020.
3. Ministry of Health and Child Care, Rapid Guidance on HIV Service Delivery in COVID-19 Context, Version 3: 31 March 2020. Zimbabwe MOHCC.
4. Wilkinson T, Chalkidou K, Walker D, Lopert R, Teerawattananon Y, Chantarastpornchit V. et al. Methods for Economic Evaluation Project (MEEP), NICE International, January 2014. https://www.idsiehealth.org/wp-content/uploads/2015/01/MEEP-report.pdf
5. Jewell B, Mudimu E, Stover J, Ten Brink D, Phillips AN, Smith JA et al. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-10: results from multiple mathematical models. Lancet HIV. August 6, 2020. https://doi.org/10.1016/S2352-3018(20)30211-3.
6. Stover J, Bollinger L, Iazzaola JA, Loures L, DeLay P, Ghys PD What is Required to End the AIDS Epidemic as a Public Health Threat by 2030? The Cost and Impact of the Fast-Track Approach (2016) PLoS ONE 11(5):e0154893: https://doi.org/10.1371/journal.pone.0154893 PMID: 27159260
7. Bershteyn A, Klein DJ, Eckhoff PA. Age-targeted HIV treatment and primary prevention as a ‘ring fence’ to efficiently interrupt the age patterns of transmission in generalized epidemic settings in South Africa. International Health 2016 8(4), 277–285. https://doi.org/10.1093/inthealth/iwt010 PMID: 27008897
8. Bershteyn A, Gerardin J, Bridenbecker D, et al. Implementation and applications of EMOD, an individual-based multi-disease modeling platform. Pathog Dis. 2018; 76(5). https://doi.org/10.1093/femsdp/ fy059 PMID: 29986020
9. Bershteyn A, Klein DJ, Eckhoff PA. Age-dependent partnering and the HIV transmission chain: a micro-simulation analysis. J R Soc Interface. 2013; 10(88):20130613 https://doi.org/10.1098/rsif.2013.0613 PMID: 23985734
10. Selinger C, Dimitrov D, Welkoff P, Bershteyn A. The future of a partially effective HIV vaccine: assessing limitations at the population level. International journal of public health 2019. 64(6):957–964. https://doi.org/10.1007/s00038-019-01234-z PMID: 30982082
11. Selinger C, Bershteyn A, Dimitrov DT, et al. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. Vaccine. 2019; 37(16):2258–2267. https://doi.org/10.1016/j.vaccine.2019.02.073 PMID: 30890385
12. Mudimu E, Peebles K, Mukandavire Z, Nightingale E, Sharma M, Medley GF, et al. (2020) Individual and community-level benefits of PrEP in western Kenya and South Africa: Implications for population prioritization of PrEP provision. PLoS ONE 15(12): e0244761. https://doi.org/10.1371/journal.pone.0244761 PMID: 33382803
13. Sharma M, Mudimu E, Simeon K, Bershteyn A, Dorward J, Violette L et al. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study. The Lancet HIV 2020. https://doi.org/10.1016/S2352-3018(20)30279-4 PMID: 33347810
14. Klein DJ, Bershteyn A, Eckhoff PA. Dropout and re-enrollment: implications for epidemiological projections of treatment programs. AIDS. 2014; 28:S47–S59 https://doi.org/10.1097/QAD.0000000000000081 PMID: 24468946
15. Abbas K, Procter SR, van Zanvoort K, Clark A, Funk S, Mengistu T et al. Routine childhood immunization during the COVID-19 pandemic in Africa: a benefit-risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. Lancet Glob Health 2020, July 17, 2020, https://doi.org/10.1016/S2214-109X(20)30308-9 PMID: 32687792
16. Byrne AW, McEvoy D, Collins AB, Hunt K, Casey M, Barber A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open 2020; 10:e039856. https://doi.org/10.1136/bmjopen-2020-039856 PMID: 32759252
17. Mwananyanda L, Gill CJ, McLeod W, Kwenda G, Pleciak R, Mupila Z et al. COVID-19 deaths detected in a systematic post-mortem surveillance study in Africa. medRxiv doi: https://doi.org/10.1101/2020.12.22.20248327
18. CDC. Weekly Updates by Select Demographic and Geographic Characteristics, December 30, 2020. https://www.cdc.gov/nchs/nvss/vsr/covid_weekly/index.htm
19. Boehmer TK, DeVies J, Caruso E, et al. Changing Age Distribution of the COVID-19 Pandemic—United States, May—August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1404–1409. https://doi.org/10.15585/mmwr.mm6939e1 PMID: 33001872
20. Kerr CC, Stuart RM, Mistry D, Abeyesuriya RG, Hart G, Rosenfeld K, et al. Covasim: an agent-based model of COVID-19 dynamics and interventions. https://www.medrxiv.org/content/10.1101/2020.05.10.20097469v1 PMID: 34310589
21. Haacker Markus, Timothy B Hallett, Rifat Atun, On discount rates for economic evaluations in global health, Health Policy and Planning, Volume 35, Issue 1, February 2020, Pages 107–114, https://doi.org/10.1093/heapol/czz127 PMID: 31625564
22. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012 Jan 28; 26(3). https://doi.org/10.1097/QAD.0b013e32834dcec9 PMID: 22089374

23. Mahase E. Covid-19: What do we know about “long covid”? BMJ. 2020 Jul 14; 370:m2815. https://doi.org/10.1136/bmj.m2815 PMID: 32665317

24. Celum C, Barnabas R, Cohen M, Collier A, El-Sadr W, Holmes K et al. Covid-19, Ebola, and HIV—Leveraging Lessons to Maximize Impact. N Engl J Med 2020; 383:e106. https://doi.org/10.1056/NEJMp2022269 PMID: 33027565